Document is current
Any future updates will be listed below
-
Authors
Coiro, Stefano https://orcid.org/0000-0001-9463-5055
Lacomblez, Claire
Duarte, Kevin
Gargani, Luna
Rastogi, Tripti
Chouihed, Tahar
Girerd, Nicolas
- License Information
-
More Information
Article History
Received: 11 September 2023
Accepted: 23 April 2024
First Online: 23 May 2024
Declarations
:
: NG reports consulting fees from Astrazeneka, Bayer, Boehringer, Echosens, Lilly, Novartis, Novonordisk, NP medical. The other authors declare that they have no conflict of interest to declare.
: All studies were in line and/or approved by the respective local regulations.
: 1) PURPLE study: patients were informed through a notice at admission and could refuse their inclusion in the study, although no formal consent was required in keeping with the framework of the Commission Nationale de l’Informatique et des Libertés (CNIL). 2) NANCY AHF study: no formal consent was required in keeping with the framework of the CNIL; collection of patient files was approved by the CNIL, in keeping with French law for single-centre usual care observational studies. 3) REMI study: for the prospective REMI study, all subjects gave signed informed consent to participate.
